in this issue
Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients
Pharma/fine chemicals roundup—23 April
12:16 PM MDT | April 23, 2013 | Deepti Ramesh
Hikma to retain injectables business Hikma Pharmaceuticals (London) says it has concluded a review of the strategic options for its global Injectables business and decided that this business should remain part of the Hikma group. Hikma's operations are conducted through three pharmaceutical businesses—branded, injectables, and generics, based mainly in the Mideast and North Africa regions, the United States, and Europe. Hikma recorded sales of about $1.1 billion in 2012. “After a thorough review of strategic options for the injectables business, we...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee